Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...

CSL shares slump to levels last seen in December 2017. The post Why the CSL share price just hit a 9-year low appeared first ...

A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...

I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine ("Seqirus") and plasma therapy ("Behring") segments. Seqirus is witnessing revenue declines as a result of ...

Shares of the Australia-based CSL Ltd. (AU:CSL) fell by over 4% as of writing despite the company achieving higher profit in FY24. The company reported an NPAT (net profit after tax) attributable to ...

As investors, we’re irresistibly drawn to milestones, and the past year has provided a jackpot of them. The ASX stormed past 8,000, Bitcoin soared beyond US$100,000, NVIDIA hit a mind-boggling US$3 ...

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...

Earnings call CSL reported H1 FY26 revenue of $8.3B (down 4% YoY, constant currency) and NPATA of $1.9B (down 7%). Reported NPAT fell 81% due to $1.05B in impairments. Despite challenges, full-year ...

Earnings call CSL reported H1 FY26 revenue of $8.3B (down 4% YoY, constant currency) and NPATA of $1.9B (down 7%). Reported NPAT fell 81% due to $1.05B in impairments. Despite challenges, full-year ...

CSL to downsize one-third of R&D division, AFR reports Company has not confirmed the number of job reductions Shares up 3% at over 6-week high July 15 (Reuters) - Australian biotech giant CSL Ltd (CSL ...